glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
== Regulation == While most steps in gluconeogenesis are the reverse of those found in glycolysis, three regulated and strongly endergonic reactions are replaced with more kinetically favorable reactions. Hexokinase/glucokinase, phosphofructokinase, and pyruvate kinase enzymes of glycolysis are replaced with glucose-6-phosphatase, fructose-1,6-bisphosphatase, and PEP carboxykinase/pyruvate carboxylase. These enzymes are typically regulated by similar molecules, but with opposite results. For example, acetyl CoA and citrate activate gluconeogenesis enzymes (pyruvate carboxylase and fructose-1,6-bisphosphatase, respectively), while at the same time inhibiting the glycolytic enzyme pyruvate kinase. This system of reciprocal control allow glycolysis and gluconeogenesis to inhibit each other and prevents a futile cycle of synthesizing glucose to only break it down. Pyruvate kinase can be also bypassed by 86 pathways not related to gluconeogenesis, for the purpose of forming pyruvate and subsequently lactate; some of these pathways use carbon atoms originated from glucose. The majority of the enzymes responsible for gluconeogenesis are found in the cytosol; the exceptions are mitochondrial pyruvate carboxylase and, in animals, phosphoenolpyruvate carboxykinase. The latter exists as an isozyme located in both the mitochondrion and the cytosol. The rate of gluconeogenesis is ultimately controlled by the action of the enzyme fructose-1,6-bisphosphatase, which is also regulated through signal transduction by cAMP and its phosphorylation.
Italy was a postwar operator of P-51Ds; deliveries were slowed by the Korean War, but between September 1947 and January 1951, by MDAP count, 173 examples were delivered. They were used in all the AMI fighter units: 2, 3, 4, 5, 6 and 51 Stormo (wing), plus some employed in schools and experimental units. Considered a "glamorous" fighter, P-51s were even used as personal aircraft by several Italian commanders. Some restrictions were placed on its use due to unfavorable flying characteristics. Handling had to be done with much care when fuel tanks were fully used, and several aerobatic maneuvers were forbidden. Overall, the P-51D was highly rated even compared to the other primary postwar fighter in Italian service, the Supermarine Spitfire, partly because these P-51Ds were in very good condition in contrast to all other Allied fighters supplied to Italy. Phasing out of the Mustang began in mid-1958. Japan The P-51C-11-NT Evalina, marked as "278" (former USAAF serial: 44-10816) and flown by 26th FS, 51st FG, was hit by gunfire on 16 January 1945 and belly-landed on Suchon Airfield in China, which was held by the Japanese. The Japanese repaired the aircraft, roughly applied Hinomaru roundels and flew the aircraft to the Fussa evaluation center (now Yokota Air Base) in Japan. Netherlands
== Successor == A successor mod, Firearms: Source, was created by a different development team for the Source engine. It was released on July 23, 2010. The initial release included eight maps, five game modes, and 31 weapons. Giochi per il mio computer gave the mod a rating of two out of five.
== Symptoms == Polycythemia is often asymptomatic; patients may not experience any notable symptoms until their red cell count is very high. For patients with significant elevations in hemoglobin or hematocrit (often from polycythemia vera), some non-specific symptoms include:
=== Males === While anorexia nervosa is more commonly found in women, it can also affect men, with a lifetime prevalence of 0.3% in men. However, a lack of awareness of eating disorders in males may lead to underdiagnosis and underreporting. This can include a lack of knowledge about what kinds of behaviors males with eating disorders might display, as they differ slightly from those found in females, with a 2009 survey showing that females are more inclined to report fasting, body checking, and body avoidance, whereas males are more prone to report overeating. Due to this limited knowledge of how anorexia nervosa is presented in males, it often takes men longer to be diagnosed and receive treatment than women. An additional difference is in the use of supplements to affect bodyweight, with women being more prone to using diet pills and men being more prone to using anabolic steroids. Moreover, men who exhibit symptoms of anorexia may not meet the BMI criteria outlined in the DSM-IV due to having more muscle mass and therefore a higher bodyweight. Consequently, a subclinical diagnosis, such as Eating Disorder Not Otherwise Specified (ED-NOS) in the DSM-IV or Other Specified Feeding or Eating Disorder (OSFED) in the DSM-5, is often made instead. Men with anorexia may also experience body dysmorphia, reporting their bodies to be twice as large than in actuality, and body dissatisfaction, especially with regard to muscularity and body composition. Men tend to place more emphasis on a muscular build as opposed to pursuing thinness.
Sources: en.wikipedia.org
Southern Association, previously Class A1 (1936–1945) Texas League, previously Class A1 (1936–1942; idle for three seasons during World War II) The Texas League remained in Double-A for the next 75 years. During this time, there were limited changes to leagues at the Double-A level:
== Career == Tew was appointed the G. Willing Chair in Cancer Research at the Medical University of South Carolina from 1999 to 2004. He was the Director of the Developmental Cancer Therapeutics Program at Hollings Cancer Center from 2004 to 2019, and serves as a professor in the Department of Cell & Molecular Pharmacology at the Medical University of South Carolina. Tew has been the John C. West Chair in Cancer Research at the Medical University of South Carolina since 2004. Tew held the position of Associate Editor from 1993 to 2007 and later assumed the role of Senior Editor in the Experimental Therapeutics, Molecular Targets, and Chemical Biology Section from 2007 to 2018 for the journal Cancer Research. Concurrently, he held editorial positions including, Editor for Cellular Pharmacology, and Editor-in-Chief of Journal of Pharmacology and Experimental Therapeutics. Tew has been the Editor (USA) of Biomedicine & Pharmacotherapy since 2002 and Serial Editor for Advances in Cancer Research since 2011. Additionally, he has held appointments at InVaMet Therapeutics and the Greehey Children's Cancer Research Institute Scientific External Advisory Board since 2019.
===== Behavioral treatments ===== A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these. Additionally, research on the neurobiological effects of physical exercise suggests that daily aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of drug addiction and is an effective adjunct therapy (i.e., a supplemental treatment) for amphetamine addiction. Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions. In particular, aerobic exercise decreases psychostimulant self-administration, reduces the reinstatement (i.e., relapse) of drug-seeking, and induces increased dopamine receptor D2 (DRD2) density in the striatum. This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density.
Pentachlorophenol (PCP) is an organochlorine compound used as a pesticide and a disinfectant. First produced in the 1930s, it is marketed under many trade names. It can be found as pure PCP, or as the sodium salt of PCP, the latter of which dissolves easily in water. It can be biodegraded by some bacteria, including Sphingobium chlorophenolicum.
Sources: en.wikipedia.org
Stickland fermentation or The Stickland Reaction is the name for a chemical reaction that involves the coupled oxidation and reduction of amino acids to organic acids. The electron donor amino acid is oxidised to a volatile carboxylic acid one carbon atom shorter than the original amino acid. For example, alanine with a three carbon chain is converted to acetate with two carbons. The electron acceptor amino acid is reduced to a volatile carboxylic acid the same length as the original amino acid. For example, glycine with two carbons is converted to acetate. In this way, amino acid fermenting microbes can avoid using hydrogen ions as electron acceptors to produce hydrogen gas. Amino acids can be Stickland acceptors, Stickland donors, or act as both donor and acceptor. Only histidine cannot be fermented by Stickland reactions, and is oxidised. With a typical amino acid mix, there is a 10% shortfall in Stickland acceptors, which results in hydrogen production. Under very low hydrogen partial pressures, increased uncoupled anaerobic oxidation has also been observed. It occurs in proteolytic clostridia such as: C. perfringens, Clostridioides difficile, C. sporogenes, and C. botulinum. Additionally, sarcosine and betaine can act as electron acceptors.
==== Montessori ==== Prince George's County Public Schools has implemented two facilities dedicated to the Montessori instructional program — the Robert Goddard Montessori School and the John Hanson Montessori School. As dedicated facilities, these schools do not have a neighborhood attendance area. Entry into the program is through the random lottery application process only. The Montessori Primary Program for children ages 3 to 6 years old is based on the Montessori educational philosophy. Taught by Montessori accredited teachers, young children are guided in developing an inner discipline, strengthening their coordination, and extending their concentration span. These accomplishments result with their readily learning to read, write and grasp mathematics. The program consists of a half-day morning for preschoolers (ages 3 ). Children older than four must be enrolled in a certified Montessori program to be accepted into the program. The Montessori Lower Elementary Program is designed for students ages 6 to 9 years old with prior Montessori experience. Rapid growth and learning is observed in classrooms filled with appropriate educational materials. The Montessori Upper Elementary Program continues for the next age grouping of students ages 9–12 with prior Montessori experience. Taught by Montessori accredited teachers, these elementary program students study an integrated curriculum that includes: mathematics, geometry, language, cultural studies, astronomy, biology, chemistry, geography, history, geology, philosophy, art, music and physical education.
=== Location === The SA node is located in the wall (epicardium) of the right atrium, laterally to the entrance of the superior vena cava in a region called the sinus venarum (hence sino- + atrial). It is positioned roughly between a groove called the crista terminalis located on the internal surface of the heart and the corresponding sulcus terminalis, on the external surface. These grooves run between the entrance of the superior vena cava and the inferior vena cava.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。